Copyright
©The Author(s) 2024.
World J Transplant. Mar 18, 2024; 14(1): 87532
Published online Mar 18, 2024. doi: 10.5500/wjt.v14.i1.87532
Published online Mar 18, 2024. doi: 10.5500/wjt.v14.i1.87532
Figure 6 Comparison of progression free survival and overall survival between full dose melphalan (MEL) (200 mg/m2), low or reduced intensity MEL (100 mg/m2), and modified MEL (100 mg/m2).
PFS: Progression free survival; OS: Over survival; MEL: Melphalan.
- Citation: Maqbool S, Baloch MF, Khan MAK, Khalid A, Naimat K. Autologous hematopoietic stem cell transplantation conditioning regimens and chimeric antigen receptor T cell therapy in various diseases. World J Transplant 2024; 14(1): 87532
- URL: https://www.wjgnet.com/2220-3230/full/v14/i1/87532.htm
- DOI: https://dx.doi.org/10.5500/wjt.v14.i1.87532